Rapport Therapeutics, Inc. Common StockRAPP
▼ NegativeCapitalrelevance
Reports wider Q2 net loss of $56.6M vs $26.7M prior year.
Impact on stocks 1
Biotech & Genomic Medicine
Rapport Therapeutics, Inc. Common StockRapport Therapeutics reported a second-quarter net loss of $56.6 million, compared to $26.7 million in the prior year period. The company expects that its cash, cash equivalents, and short-term investments as of June 30, 2026 will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2029.
Rapport Therapeutics, Inc. Common StockReports wider Q2 net loss of $56.6M vs $26.7M prior year.